These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20406025)

  • 1. Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospital-based donor center.
    Gribble DM; Chaffin DJ; Bryant BJ
    Immunohematology; 2009; 25(4):170-3. PubMed ID: 20406025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic phlebotomy procedures and their impact on a rural hospital's red blood cell inventory and fiscal stature.
    Flynn RC; Bryant BJ
    Transfusion; 2011 Dec; 51(12 Pt 2):2761-6. PubMed ID: 22150687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemochromatosis subjects as allogeneic blood donors: a prospective study.
    Leitman SF; Browning JN; Yau YY; Mason G; Klein HG; Conry-Cantilena C; Bolan CD
    Transfusion; 2003 Nov; 43(11):1538-44. PubMed ID: 14617312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis.
    Winters AC; Tremblay D; Arinsburg S; Mascarenhas J; Schiano TD
    Hepatology; 2018 Mar; 67(3):1150-1157. PubMed ID: 28902419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemochromatosis probands as blood donors.
    Barton JC; Grindon AJ; Barton NH; Bertoli LF
    Transfusion; 1999 Jun; 39(6):578-85. PubMed ID: 10378837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Double RBC Collection by Blood Cell Separators.
    Kitpoka P; Chanthet S; Chongkolwatana V; Chuansumrit A; Kunakorn M
    J Med Assoc Thai; 2016 Jan; 99(1):88-96. PubMed ID: 27455830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy.
    Muncunill J; Vaquer P; Galmés A; Obrador A; Parera M; Bargay J; Besalduch J
    J Clin Apher; 2002; 17(2):88-92. PubMed ID: 12210712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of phlebotomy among persons with hemochromatosis.
    McDonnell SM; Grindon AJ; Preston BL; Barton JC; Edwards CQ; Adams PC
    Transfusion; 1999 Jun; 39(6):651-6. PubMed ID: 10378847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.
    Franchini M; Gandini G; Veneri D; de Matteis G; Federici F; Solero P; Aprili G
    Transfusion; 2004 Jun; 44(6):833-7. PubMed ID: 15157247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.
    Rombout-Sestrienkova E; van Noord PA; van Deursen CT; Sybesma BJ; Nillesen-Meertens AE; Koek GH
    Transfus Apher Sci; 2007 Jun; 36(3):261-7. PubMed ID: 17569592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.
    Casanova-Esteban P; Guiral N; Andrés E; Gonzalvo C; Mateo-Gallego R; Giraldo P; Paramo JA; Civeira F
    Metabolism; 2011 Jun; 60(6):830-4. PubMed ID: 20846699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 May; 80(99):29841-906. PubMed ID: 26003966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
    Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
    J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of donated red blood cell components from patients with hereditary hemochromatosis.
    Sut C; Hamzeh-Cognasse H; Laradi S; Bost V; Aubrège C; Acquart S; Vignal M; Boutahar N; Arthaud CA; Ange Eyraud M; Pozzetto B; Tiberghien P; Garraud O; Cognasse F
    Transfusion; 2017 Jan; 57(1):166-177. PubMed ID: 27807848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Aug; 72(164):48765-801. PubMed ID: 17886394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements.
    Olynyk JK; Luxon BA; Britton RS; Bacon BR
    Am J Gastroenterol; 1998 Mar; 93(3):346-50. PubMed ID: 9517637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood collection and transfusion in the United States in 2001.
    Sullivan MT; Cotten R; Read EJ; Wallace EL
    Transfusion; 2007 Mar; 47(3):385-94. PubMed ID: 17319817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost containment through a hospital-based blood donor center.
    Miskowicz J
    Clin Lab Manage Rev; 1996; 10(4):332-7. PubMed ID: 10159523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood collection and transfusion in the United States in 1999.
    Sullivan MT; Wallace EL
    Transfusion; 2005 Feb; 45(2):141-8. PubMed ID: 15660821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis.
    Sanchez AM; Schreiber GB; Bethel J; McCurdy PR; Glynn SA; Williams AE; Gilcher R;
    JAMA; 2001 Sep; 286(12):1475-81. PubMed ID: 11572740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.